Skip to main content

Fogden DDW 2016 Endobarrier

One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) therapy in Suboptimally Controlled Type 2 Diabetes: a Randomised Controlled Trial

E Fogden*, P Sen Gupta, M Anderson, B Hayee, RS Drummond, BM McGowan, SA Amiel, REJ Ryder